Johnson & Johnson (NYSE:JNJ) Stock Rating Reaffirmed by BMO Capital Markets

BMO Capital Markets restated their buy rating on shares of Johnson & Johnson (NYSE:JNJ) in a research note released on Friday, September 1st. BMO Capital Markets currently has a $145.00 price objective on the stock.

JNJ has been the topic of a number of other reports. Credit Suisse Group reaffirmed a buy rating on shares of Johnson & Johnson in a research report on Friday, August 4th. Vetr downgraded shares of Johnson & Johnson from a buy rating to a hold rating and set a $128.90 target price on the stock. in a research report on Monday, May 8th. Alembic Global Advisors downgraded shares of Johnson & Johnson from a neutral rating to an underweight rating in a research report on Friday, July 21st. UBS AG reaffirmed a buy rating and issued a $148.00 target price on shares of Johnson & Johnson in a research report on Thursday, August 31st. Finally, Wells Fargo & Company reaffirmed a market perform rating and issued a $135.00 target price (up from $132.00) on shares of Johnson & Johnson in a research report on Thursday, July 6th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $134.60.

Johnson & Johnson (NYSE JNJ) traded up 0.20% on Friday, hitting $134.45. 15,522,011 shares of the company’s stock were exchanged. The stock has a market cap of $360.86 billion, a P/E ratio of 22.75 and a beta of 0.79. The firm has a 50 day moving average price of $132.62 and a 200-day moving average price of $129.18. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.74 EPS. Analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://ledgergazette.com/2017/09/17/bmo-capital-markets-reaffirms-buy-rating-for-johnson-johnson-jnj.html.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were paid a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.50%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.

In related news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after acquiring an additional 3,023,110 shares in the last quarter. BlackRock Inc. increased its holdings in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after acquiring an additional 4,332,612 shares in the last quarter. State Street Corp increased its holdings in Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after acquiring an additional 6,656,371 shares in the last quarter. Norges Bank purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $3,220,322,000. Finally, FMR LLC increased its holdings in Johnson & Johnson by 5.9% in the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after acquiring an additional 1,509,745 shares in the last quarter. 66.00% of the stock is owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply